Robert Davis
Summary
Robert Davis has served as Merck’s president and chief executive officer since July 1, 2021, and as chairman since December 1, 2022.
Biography
Davis joined Merck in 2014 as executive vice president and chief financial officer, with additional responsibility for real estate, corporate strategy, and business development. In 2016, his responsibilities expanded to include information technology and procurement as part of the company’s Global Services organization. He became president in April 2021 before taking over as CEO later that year. Before Merck, Davis spent a decade at Baxter International, where he held leadership roles including corporate vice president and president of the Medical Products business, president of the Renal business, chief financial officer, and treasurer. Earlier in his career, he spent more than 14 years at Eli Lilly in finance and operating roles. Davis holds a bachelor’s degree in finance from Miami University, an MBA from Northwestern University’s Kellogg School of Management, and a JD from Northwestern University’s Pritzker School of Law.
Notable achievements
- Oversaw continued expansion of Keytruda, which generated $31.7 billion in worldwide sales in 2025.
- Led the launch and early commercial growth of Winrevair, which reached $1.4 billion in 2025 sales.
- Advanced Merck’s pipeline through business development, including the acquisition of Acceleron and the 2025 acquisition of Verona Pharma.
- Guided Merck through the 2021 separation of its established-products business into Organon while becoming CEO.
Problem areas / controversies
- Gardasil sales weakened sharply in China, leading Merck to pause shipments temporarily to reduce channel inventory.
- Merck remains heavily dependent on Keytruda, creating a significant long-term challenge as major U.S. patent protections approach expiration later this decade.
- The company faces continuing pricing and reimbursement pressure, including the effects of U.S. Medicare drug-price negotiations and other cost-containment measures.
- There is no widely reported personal misconduct controversy involving Davis; the main criticisms concern business concentration, product exposure, and execution risks.